Juno Therapeutics, Inc.
JUNO
JUNO was delisted on the 5th of March, 2018.
154 hedge funds and large institutions have $2.54B invested in Juno Therapeutics, Inc. in 2015 Q2 according to their latest regulatory filings, with 57 funds opening new positions, 55 increasing their positions, 23 reducing their positions, and 23 closing their positions.
148% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 23
139% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 23
28% more funds holding
Funds holding: 120 → 154 (+34)
14% less capital invested
Capital invested by funds: $2.96B → $2.54B (-$417M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
60% less call options, than puts
Call options by funds: $20.3M | Put options by funds: $51.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$28.6M |
| 2 |
State Street
Boston,
Massachusetts
|
+$24.4M |
| 3 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$23.9M |
| 4 |
JP Morgan Chase
New York
|
+$21M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$18.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VM
VHCP Management
New York
|
-$88.1M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$61.1M |
| 3 |
CM
Crestline Management
Fort Worth,
Texas
|
-$58.2M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$21M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
-$15M |
JUNO Hedge Fund Activity: Q2 2015 in Review
154 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Juno Therapeutics, Inc. (JUNO) for Q2 2015, worth a combined $2.54B — down 14% from $2.96B a quarter earlier.
Buyers outnumbered sellers: 57 funds opened new JUNO positions and 23 closed out — a net gain of 34 holders — while 55 added to existing stakes and 23 trimmed.
The largest buyer was Capital World Investors, adding an estimated $28.6M. The largest seller was VHCP Management, cutting an estimated $88.1M.
- 154 institutional investors held Juno Therapeutics, Inc. (JUNO) as of Q2 2015, up from 120 in Q1 2015.
- Funds reported $2.54B of Juno Therapeutics, Inc. stock for Q2 2015, down 14% quarter-over-quarter.
- 57 funds opened new Juno Therapeutics, Inc. positions in Q2 2015 and 23 closed out, a net change of +34 holders.
- The largest Juno Therapeutics, Inc. buyer in Q2 2015 was Capital World Investors, an estimated $28.6M added.
- The largest Juno Therapeutics, Inc. seller in Q2 2015 was VHCP Management, an estimated $88.1M sold.
Based on aggregated 13F filings for Q2 2015.